2026-04-17T17:18:07Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/131302025-10-24T10:56:21Zcom_2072_451667com_2072_378040col_2072_451668

Fundamentals of lipoprotein(a) request and quantification in the clinical laboratory ARROBAS VELILLA, TERESA Fernández Prendes, Carla Calmarza, Pilar Camós Anguila, Sílvia Candás-Estébanez, Beatriz Castro-Castro, Maria Jose Ceacero-Marín, David Amigó, Núria Colesterol Lipoproteïna A CHEMICALS AND DRUGS::Lipids::Membrane Lipids::Sterols::Cholesterol CHEMICALS AND DRUGS::Lipids::Lipoproteins::Lipoprotein(a) DISEASES::Cardiovascular Diseases ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques COMPUESTOS QUÍMICOS Y DROGAS::compuestos policíclicos::compuestos con anillos de fusión::esteroides::colestanos::colestenos::colesterol COMPUESTOS QUÍMICOS Y DROGAS::lípidos::lipoproteínas::lipoproteína ENFERMEDADES::enfermedades cardiovasculares TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::técnicas de laboratorio clínico Colesterol; Lipoproteïna A Colesterol; Lipoproteína(a) Cholesterol; Lipoprotein(a) Cardiovascular diseases keep being the leading cause of mortality in Spain. Efforts should be intensified to identify new risk factors that may contribute to increasing cardiovascular risk. Lipoprotein(a) (Lp(a)) has been associated with a higher risk for developing aortic valve stenosis, heart failure, ischemic stroke, ischemic heart disease and peripheral arterial disease. Hyperlipoproteinemia(a) is a common health problem. Between 10 and 30 % of the world population have Lp(a) values exceeding 50 mg/dL. The scientific evidence provided in the recent years confirms an independent association between Lp(a) and the risk for having an arteriosclerotic cardiovascular event. This finding, added to the emergence of new specific therapies for reducing Lp(a) has raised interest in the quantification of this lipoprotein. The objective of this paper was to perform a review of the evidence available to identify the patients who will benefit from undergoing Lp(a) testing and determine the recommended quantification methods, the desirable concentrations, and the role of Lp(a) determination in reclassifying the cardiovascular risk of patients. 2025-10-24T10:56:21Z 2025-10-24T10:56:21Z 2025-10-24T10:56:21Z 2025-05-26T07:14:24Z 2025-05-26T07:14:24Z 2025 2025-03-03 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/13130 Advances in Laboratory Medicine;6(1) https://doi.org/10. 1515/almed-2024-0090. Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess De Gruyter Scientia